| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present invention refers to certain (R)-arylalkylamino derivatives of formula , wherein R is specified in the following values: - 2-thiazolyl substituted by a trifluoromethyl group; -CORa, SO2Ra, wherein Ra is specified in the following values -C1-C5-alkyl, C3-C6- cycloalkyl, phenyl, a heteroaryl group specified in thiophen, furan and pyridine with heteroaryl being unsubstituted or substituted by a group specified in COOH and C1-C4-acyloxy; - ë-aminoalkylamino group of formula , wherein X represents: - linear or branched C1-C6 alkylene; R2 and R3 together with N atom bound therewith form a 3-7-member nitrogen-containing heterocyclic ring of formula , wherein Y represents a single bond; and p is equal to 0 or represents an integer 1 to 3; R1 represents linear or branched C1-C5 alkyl; Ar represents a phenyl group substituted by one or more groups independently specified in benzoyl, heteroarylcarbonyl wherein the heteroaryl group represents furan, 4'-trifluoromethane sulphonyloxy-, 4'-[1-methyl-1-(phenylsulphonyl)ethyl]- and 4'-benzole sulphonyloxy-. The compounds under the invention provides unexpectedly strong inhibiting action on C5a-induced chemotaxis of human PMN. ^ EFFECT: preparing (R)-arylalkylamino derivatives applicable in treating the pathologies dependent from chemotaxic activity of neutrophils and monocytes induced by the C5a complement fraction. ^ 6 cl, 1 tbl, 10 ex |
